RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT/mTOR Signaling Pathway
Doxorubicin (DOX) is an effective chemotherapeutic agent that plays an unparalleled role in cancer treatment. However, its serious dose-dependent cardiotoxicity, which eventually contributes to irreversible heart failure, has greatly limited the widespread clinical application of DOX. A previous stu...
| Huvudupphovsmän: | , , , , , |
|---|---|
| Materialtyp: | Artikel |
| Språk: | English |
| Publicerad: |
MDPI AG
2022-02-01
|
| Serie: | Biomolecules |
| Ämnen: | |
| Länkar: | https://www.mdpi.com/2218-273X/12/2/299 |